NASDAQ : XNCR
Xencor, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 29.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.21B |
| Enterprise Value | 1.82B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 74.35M |
| Shares Outstanding | 74.35M |
| Shares Change (YoY) | +5.22% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 84.62% |
| Float | 54.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.96 |
| Forward PS | 18.09 |
| PB Ratio | 4.40 |
| P/TBV Ratio | 4.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 17.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.39 |
| Quick Ratio | 6.09 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.98 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -29.07% |
| Return on Assets (ROA) | -16.83% |
| Return on Invested Capital (ROIC) | -93.39% |
| Return on Capital Employed (ROCE) | -33.60% |
| Weighted Average Cost of Capital (WACC) | 9.42% |
| Revenue Per Employee | $403,742 |
| Profits Per Employee | -$628,173 |
| Employee Count | 260 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.48M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +101.97% |
| 50-Day Moving Average | 25.78 |
| 200-Day Moving Average | 17.04 |
| Relative Strength Index (RSI) | 67.25 |
| Average Volume (20 Days) | 1,720,375 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.27M |
| Short Previous Month | 16.37M |
| Short % of Shares Out | 16.50% |
| Short % of Float | 22.61% |
| Short Ratio (days to cover) | 8.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 104.97M |
| Gross Profit | -150.79M |
| Operating Income | -216.08M |
| Pretax Income | -160.85M |
| Net Income | -163.33M |
| EBITDA | -205.90M |
| EBIT | -216.08M |
| Loss Per Share | -$2.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 456.45M |
| Total Debt | 170.11M |
| Net Cash | 394.88M |
| Net Cash Per Share | $5.31 |
| Equity (Book Value) | 503.23M |
| Book Value Per Share | 6.77 |
| Working Capital | 441.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -205.81M |
| Capital Expenditures | -2.47M |
| Depreciation & Amortization | 10.17M |
| Net Borrowing | n/a |
| Free Cash Flow | -208.29M |
| FCF Per Share | -$2.80 |
Margins
| Measure | Value |
|---|
| Gross Margin | -143.65% |
| Operating Margin | -205.84% |
| Pretax Margin | -153.23% |
| Profit Margin | -155.59% |
| EBITDA Margin | -196.15% |
| EBIT Margin | -205.84% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.22% |
| Shareholder Yield | -5.22% |
| Earnings Yield | -7.32% |
| FCF Yield | -9.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $41.58 |
| Price Target Difference | 39.77% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | -3.29% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.43 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |